Abstract:Background: The level of scientific evidence in National Comprehensive Cancer Network (NCCN) guidelines for malignant hematological conditions haven't been recently investigated. We describe the distribution of categories of evidence and consensus (EC) among the 10 most common hematologic malignancies with regard to recommendations for staging, initial and salvage therapy, and surveillance. Methods: We reviewed the level of evidence for the 10 most common hematological malignancies by incidence in the United States as of 2020. The NCCN definitions for EC are: category 1, high level of evidence, such as randomized controlled trials, with uniform consensus; category 2A, lower level of evidence with uniform consensus; category 2B, lower level of evidence without a uniform consensus but with no major disagreement; and category 3, any level of evidence but with major disagreement. We compared our results with previously published results from 2011. Results: Of 1353 recommendations, 5%, 91%, 4%, and 1% fell into EC categories 1, 2A, 2B, and 3, respectively, while in 2011 the comparable percentages were 3%, 93%, 4%, and 0%, respectively. Recommendations with category 1 EC were found in all guidelines, except for Burkitt lymphoma. Of all therapeutic recommendations, 6.3% were category 1 EC, with the majority of these (56.4%) pertaining to initial therapy. Guidelines with highest proportions of therapeutic recommendations with category 1 EC were multiple myeloma (12.4%), chronic lymphocytic leukemia/small lymphocytic lymphoma (6.9%), and acute myeloid leukemia (5.6%). Conclusions: Recommendations in the 2020 NCCN guidelines are largely developed from lower levels of evidence but with uniform expert opinion, underscoring the urgent need and available opportunities to expand the current evidence base in malignant hematological disorders.

Non-Hodgkin's lymphomas, version 1.2013

Guidelines for NHL: updates to the management of diffuse large B-cell lymphoma and new guidelines for primary cutaneous CD30+ T-cell lymphoproliferative disorders and T-cell large granular lymphocytic leukemia

[Evaluation of Chromosomal Abnormalities in Non-Hodgkin's Lymphomas - Review].

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

New and developing first line pharmacotherapies for treating non-Hodgkin lymphoma

Update: The molecular spectrum of virus-associated high-grade B-cell non-Hodgkin lymphomas

Nodular lymphocyte-predominant Hodgkin lymphoma: advances in disease biology, risk stratification, and treatment

Lymphoma classification update: B-cell non-Hodgkin lymphomas

Clinical Impact of the 2016 Update to the WHO Lymphoma Classification

Hodgkin lymphoma: 2022 update on diagnosis, risk‐stratification, and management

[Lymphomas: A therapeutic update]

Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management

Targeting indolent non-Hodgkin lymphoma

Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024

Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?

Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review

NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.

Non-Hodgkin lymphoma: the clinician’s perspective—a view from the receiving end